Skip to main content
Top
Published in: Thyroid Research 1/2012

Open Access 01-12-2012 | Case report

A patient with Graves’ disease showing only psychiatric symptoms and negativity for both TSH receptor autoantibody and thyroid stimulating antibody

Authors: Hidetaka Hamasaki, Taro Yoshimi, Hidekatsu Yanai

Published in: Thyroid Research | Issue 1/2012

Login to get access

Abstract

Background

Both thyroid stimulating hormone (TSH) and thyroid stimulating antibody (TSAb) negative Graves’s disease (GD) is extremely rare. Here we present such a patient.

Case presentation

The patient was a 76-year-old woman who was diagnosed as having schizophrenia forty years ago. She did not show characteristic symptoms for hyperthyroidism, such as swelling of thyroid, exophthalmos, tachycardia and tremor, however, she showed only psychomotor agitation. Serum free triiodothyronine and free thyroxine levels were elevated and TSH level was suppressed, suggesting the existence of hyperthyroidism. However, both the first generation TSH receptor autoantibody (TRAb1) and the thyroid stimulating autoantibody (TSAb) were negative. Slightly increased blood flow and swelling was detected by thyroid echography. Thyroid scintigraphy demonstrated diffuse and remarkably elevated uptake of 123I uptake. Finally, we diagnosed her as having GD. She was treated by using methimazole, and hyperthyroidism and her psychiatric symptoms were promptly ameliorated.

Discussion

We experienced a patient with GD who did not show characteristic symptoms except for psychiatric symptoms, and also showed negativity for both TRAb1 and TSAb. Thyroid autoantibody-negative GD is extremely rare. Thyroid scintigraphy was useful to diagnose such a patient.
Appendix
Available only for authorised users
Literature
1.
go back to reference Zöphel K, Roggenbuck D, Schott M: Clinical review about TRAb assay's history. Autoimmun Rev 2010, 9: 695–700. 10.1016/j.autrev.2010.05.021PubMedCrossRef Zöphel K, Roggenbuck D, Schott M: Clinical review about TRAb assay's history. Autoimmun Rev 2010, 9: 695–700. 10.1016/j.autrev.2010.05.021PubMedCrossRef
2.
go back to reference Weetamn AP: Graves’ disease. N Engl J Med 2000, 343: 1236–1248. 10.1056/NEJM200010263431707CrossRef Weetamn AP: Graves’ disease. N Engl J Med 2000, 343: 1236–1248. 10.1056/NEJM200010263431707CrossRef
5.
go back to reference Bunevičius R, Prang AJ Jr: Thyroid disease and mental disorders: cause and effect or only comorbidity? Curr Opin Psychiatry 2010, 23: 363–368. 10.1097/YCO.0b013e3283387b50PubMedCrossRef Bunevičius R, Prang AJ Jr: Thyroid disease and mental disorders: cause and effect or only comorbidity? Curr Opin Psychiatry 2010, 23: 363–368. 10.1097/YCO.0b013e3283387b50PubMedCrossRef
6.
go back to reference Ogah OS, Timeyin AO, Kayode OA, Otukoya AS, Akinyemi RO, Adeyemi FI: Graves’ disease presenting as paranoid schizophrenia in a Nigerian woman: a case report. Cases Journal 2009, 2: 6708. 10.4076/1757-1626-2-6708PubMedCentralPubMedCrossRef Ogah OS, Timeyin AO, Kayode OA, Otukoya AS, Akinyemi RO, Adeyemi FI: Graves’ disease presenting as paranoid schizophrenia in a Nigerian woman: a case report. Cases Journal 2009, 2: 6708. 10.4076/1757-1626-2-6708PubMedCentralPubMedCrossRef
7.
go back to reference Paunkovic J, Paunkovic N: Does autoantibody-negative Graves’ disease Exist ? A second evaluation of the clinical diagnosis. Horm Metab Res 2006, 38: 53–56. 10.1055/s-2006-924979PubMedCrossRef Paunkovic J, Paunkovic N: Does autoantibody-negative Graves’ disease Exist ? A second evaluation of the clinical diagnosis. Horm Metab Res 2006, 38: 53–56. 10.1055/s-2006-924979PubMedCrossRef
8.
go back to reference Iitaka M, Morgenthaler NG, Momotani N, Nagata A, Ishikawa N, Ito K, Katayama S, Ito K: Stimulation of thyroid-stimulating hormone (TSH) receptor antibody production following painless thyroiditis. Clin Endocrinol 2004, 60: 49–53. 10.1111/j.1365-2265.2004.01939.xCrossRef Iitaka M, Morgenthaler NG, Momotani N, Nagata A, Ishikawa N, Ito K, Katayama S, Ito K: Stimulation of thyroid-stimulating hormone (TSH) receptor antibody production following painless thyroiditis. Clin Endocrinol 2004, 60: 49–53. 10.1111/j.1365-2265.2004.01939.xCrossRef
9.
go back to reference Takasu N, Kamijo K, Sato Y, Yoshimura H, Nagata A, Ochi Y: Sensitive Thyroid-stimulating antibody assay with high concentrations of polyethylene glycol for the diagnosis of Graves’ disease. Clin Exp Pharmacol Physiol 2004, 31: 3124–3319.CrossRef Takasu N, Kamijo K, Sato Y, Yoshimura H, Nagata A, Ochi Y: Sensitive Thyroid-stimulating antibody assay with high concentrations of polyethylene glycol for the diagnosis of Graves’ disease. Clin Exp Pharmacol Physiol 2004, 31: 3124–3319.CrossRef
10.
go back to reference Schott M, Feldkamp J, Bathan C, Fritzen R, Scherbaum WA, Seissler J: Detecting TSH-receptor antibodies with the recombinant TBII assay: technical and clinical evaluation. Horm Metab Res 2000, 32: 429–435. 10.1055/s-2007-978666PubMedCrossRef Schott M, Feldkamp J, Bathan C, Fritzen R, Scherbaum WA, Seissler J: Detecting TSH-receptor antibodies with the recombinant TBII assay: technical and clinical evaluation. Horm Metab Res 2000, 32: 429–435. 10.1055/s-2007-978666PubMedCrossRef
Metadata
Title
A patient with Graves’ disease showing only psychiatric symptoms and negativity for both TSH receptor autoantibody and thyroid stimulating antibody
Authors
Hidetaka Hamasaki
Taro Yoshimi
Hidekatsu Yanai
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Thyroid Research / Issue 1/2012
Electronic ISSN: 1756-6614
DOI
https://doi.org/10.1186/1756-6614-5-19

Other articles of this Issue 1/2012

Thyroid Research 1/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine